Veranova has announced a strategic investment to establish bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts facility. The investment, which exceeds $50 million, aims to enhance the company’s offering for the development and production of antibody-drug conjugates (ADCs) and
“This enterprise is lacking congressional support. The host of prior leaders in this policy space have left,” warn biodefense advocates pushing for renewed bipartisan commitment Jennifer Alton, President of Pathway Policy Group, delivered this stark assessment during a biodefense policy
At CDMO Live 2025, a panel sponsored by Lifecore Biomedical brought together industry quality leaders to discuss how quality management can become a strategic enabler rather than a compliance burden. The panel featured Jackie Klecker (EVP Quality & Development Services,
UCB, a global biopharmaceutical company focused on severe diseases, has announced plans to significantly expand its manufacturing capacity in the United States. The new facility will support the company’s growing pipeline and help ensure dependable access to its medicines. The
Samsung Biologics, a South Korea-based contract development and manufacturing organisation (CDMO), has announced the launch of Samsung Organoids, a new drug screening platform designed to support drug discovery and development. The offering marks the company’s strategic entry into the preclinical
Ratio Therapeutics Inc. has entered into an exclusive agreement with Macrocyclics Inc., granting the CDMO the global manufacturing and distribution rights to its proprietary Actinium-225 chelator, Macropa™. The deal aims to expand worldwide access to the bifunctional chelator, enabling researchers across industry
Scinai Immunotherapeutics Ltd. has announced that CEO Amir Reichman will represent the company at the BIO International Convention 2025, to be held from 16–19 June in Boston. The event will serve as a platform to highlight Scinai’s recent operational, financial, and
Scinai Immunotherapeutics Ltd. has provided contract manufacturing support to U.S.-based biopharmaceutical company Serpin Pharma for a Phase 2 clinical trial of its lead candidate, SP16. The study was conducted across Germany and Israel, marking the first time an international client used
Debiopharm, a Swiss biopharmaceutical company, has signed a co-research agreement with US-based Alkyon Therapeutics to evaluate the development of precision-targeted radioligand therapies (RLTs). The collaboration will combine Debiopharm’s proprietary AbYlink™ conjugation technology with Alkyon’s modular antibody platform targeting undisclosed tumour-associated antigens. The
Aragen, a global contract research, development and manufacturing organisation (CRDMO), has announced that its biologics manufacturing facility in Bangalore, India has completed facility and equipment qualification. The site is set to begin GMP production in late July 2025. The facility
Stay ahead of trends and best practices
Exclusive downloads and podcasts
Get invites to special events and meetups 
Help us find the most innovative and trusted suppliers in Pharma and Biotech.
